
Results of phase 3 PADRES trial of neoadjuvant axitinib in renal cell carcinoma
In the PADRES trial, neoadjuvant axitinib facilitated partial nephrectomy in patients with clear cell renal cell carcinoma and complex masses with an imperative indication for nephron-sparing surgery but no viable pathway to receive the procedure.
Lead author Kevin Hakimi discusses the background and results of the study, “Interim analysis of
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.


















